Tata India Pharma & Healthcare Fund Direct Growth
NAV as on 09-05-2025
₹ 33.19
1D
Inception Returns
13.7%
/yr
Historical NAV & Returns
Absolute
▲
▼
2654 people have invested ₹ 1.4Cr in Tata India Pharma & Healthcare Fund Direct Growth in the last three months
About Tata India Pharma & Healthcare Fund Direct Growth
Tata India Pharma & Healthcare Fund Direct Growth is an equity fund. This fund was started on 28 December, 2015. The fund is managed by Meeta Shetty. The fund could potentially beat inflation in the long-run.
Key Parameters
- Tata India Pharma & Healthcare Fund Direct Growth has ₹1223 Cr worth of assets under management (AUM) as on Mar 2025 and is less than category average.
- The fund has an expense ratio 0.7.
Returns
Tata India Pharma & Healthcare Fund Direct Growth has given a CAGR return of 13.67% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 17.65%, 23.22% and 23.28% respectively.
Holdings
Tata India Pharma & Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials. Its top holdings are Sun Pharmaceuticals Industries Ltd, Aurobindo Pharma Ltd, Cipla Ltd, Apollo Hospitals Enterprise Ltd, Lupin Ltd
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 20%For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefitDividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.
Investment objective of Tata India Pharma & Healthcare Fund Direct Growth
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 100.00. Tata India Pharma & Healthcare Fund Direct Growth has no lock in period.
Tata India Pharma & Healthcare Fund Direct Growth Overview
| Expense ratio | 0.67% |
Benchmark | Nifty Pharma TR INR |
| AUM | ₹1223 Cr |
| Inception Date | 28 December, 2015 |
| Min Lumpsum/SIP | ₹5000/₹100 |
Exit Load | 0.2% |
| Lock In | No Lock-in |
TurnOver | 28.44% |
| STCG | Selling mutual fund before 1 year, returns taxed at 20%. |
| LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
| Risk |   Very High Risk |
INDmoney Rank for Tata India Pharma & Healthcare Fund Direct Growth
Powered by IND quant engine
IND ranking is not available for this fund.
3Y returns in the top 25% of the category
Beats FD returns for both 3Y & 5Y duration
No bad points found for this fund.
Trailing Returns
as on (09-May-25)
Fund Distribution
as on (31-Mar-25)
Mid cap
34.1%
Small cap
30.2%
Large cap
29.7%
Sector Allocation
Health
97.6%
Basic Materials
2.4%
All changes are between Jan'25 and Mar'25
- This fund’s returns stands at 7.96% whereas the fund’s underlying benchmark Nifty 500 returns stands at 7.25% as on Mar'25
- This fund outperformed Nifty 500 by 0.71% in Mar'25
- AUM of the fund stands at 1.2K Cr as of Mar'25
- AUM increased by 79.7 Cr between Mar'25 and Feb'25
Top Stocks bought last month
Apollo Hospitals Enterprise Ltd's allocation increased from 3.98% to 5.66%
Metropolis Healthcare Ltd's allocation increased from 1.11% to 1.8%
Aster DM Healthcare Ltd Ordinary Shares's allocation increased from 3.31% to 3.91%
Top Stocks sold last month
Cipla Ltd's allocation decreased from 6.25 % to 5.97 %
Lupin Ltd's allocation decreased from 6.22 % to 5.2 %
Divi's Laboratories Ltd's allocation decreased from 5.21 % to 5.12 %
Small Cap allocation has gone up from 27.4% to 30.2%
Mid Cap allocation has gone up from 33% to 34.1%
Large Cap allocation has gone down from 35.9% to 29.7%
Cash allocation has gone up from 1.9% to 4.2%
Top 2 Sectors in March were Health, Basic Materials
Mar'25
Health
98%
Basic Materials
2%
Feb'25
Health
98%
Basic Materials
2%
Holdings | Weight% | 1M Change | |
|---|---|---|---|
 Sun Pharmaceuticals Industries Ltd | 11.79% | 0% | |
 Aurobindo Pharma Ltd | 7.27% | 0% | |
 Cipla Ltd | 5.97% | 0% | |
 Apollo Hospitals Enterprise Ltd | 5.66% | 39.4% | |
 Lupin Ltd | 5.2% | -15.8% |
See all
Funds | 1Y Returns | 3Y Returns | 5Y Returns | Since Inception |
|---|---|---|---|---|
Tata India Pharma & Healthcare Fund Direct Growth | 17.65% | 23.22% | 23.28% | 13.67% |
 ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth | 23.52% | 26.35% | 25.89% | 22.22% |
 SBI Healthcare Opportunities Fund Direct Growth | 22.79% | 27.26% | 25.72% | 18.13% |
 LIC MF Healthcare Fund Direct Growth | 17.88% | 18.82% | 18.18% | 19.27% |
See all
Top Growth Drivers | 1M Return |
|---|---|
 Divis Laboratories Ltd | 7.8% |
 Aurobindo Pharma Ltd | 7.6% |
 Sun Pharmaceutical Industries Ltd | 3.4% |
Loading...
We are taking more time than usual
Meeta Shetty
Fund Manager of Tata India Pharma & Healthcare Fund Direct Growth, since 9 March 2021
Top funds managed
Fund House
Tata Asset Management Limited
Total Schemes
Total AUM
₹1.85L Cr
as on 31-Mar-2025
Address
Tata Asset Management Private Limited,Mafatlal Centre, 9th Floor,,Nariman Point,,India
Phone
+912266578282
Website
kiran@tataamc.com
Mutual Fund Insights
In the last 1 year, WhiteOak Capital Pharma and Healthcare Fund Direct Growth has given 29.27% return, outperforming this fund by 11.61%.
Over the last 1 month, this fund has decreased expense ratio by 9.5% moving from 0.74 to 0.67.
In the last 5 years, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 25.89% return, outperforming this fund by 2.61% per annum.
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 0.67% which is lower than the category average expense ratio of 1.41%.
In the last 3 years, SBI Healthcare Opportunities Fund Direct Growth has given 27.26% return, outperforming this fund by 4.04% per annum.
Over the last 3 months, this fund has experienced a 5.0% drop in AUM moving from 1.28K Cr to 1.22K Cr.
Tata India Pharma & Healthcare Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 13.67% since inception which is less than its category average return of 16.33%
Fund Allocations
This fund has an allocation of 93.41% in Equity, 0% in Debt and 6.59% in Cash related instruments
AUM size ₹1223 Cr
This fund has AUM of ₹1223 Cr which is less than its category average of ₹ 1828 Cr
Expense Ratio 0.67%
This fund has an expense ratio of 0.67% which is less than its category average expense ratio of 1.44%
Most Popular Comparisons
- Compare
Tata India Pharma & Healthcare FundVs
Nippon India Pharma Fund Direct Growth
- Compare
- Tata India Pharma & Healthcare FundVs
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
- Compare
- Tata India Pharma & Healthcare FundVs
SBI Healthcare Opportunities Fund Direct Growth
- Compare
- Tata India Pharma & Healthcare FundVs
DSP Healthcare Fund Direct Growth
- Compare
- Tata India Pharma & Healthcare FundVs
LIC MF Healthcare Fund Direct Growth
More funds from Tata
5Y CAGR
▲ 24.16
3Y CAGR
▲ 22.56
5Y CAGR
▲ 29.22
5Y CAGR
▲ 36.48
5Y CAGR
▲ 31.69
Frequently Asked Questions for Tata India Pharma & Healthcare Fund Direct Growth
The current NAV of Tata India Pharma & Healthcare Fund Direct Growth is ₹33.19 as on 09-May-2025.
Existing (Absolute + CAGR) as on 09-May-2025.
Tata India Pharma & Healthcare Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | 4.32% | 4.32% |
6 Month Returns | -5.4% | -5.4% |
1 Year Returns | 17.65% | 17.65% |
3 Years Returns | 87.09% | 23.22% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
0.67% as on April 2025
₹1223 Cr as on April 2025
Sun Pharmaceuticals Industries Ltd(11.79%), Aurobindo Pharma Ltd(7.27%), Cipla Ltd(5.97%), Apollo Hospitals Enterprise Ltd(5.66%), Lupin Ltd(5.2%) as on April 2025
The alpha ratio for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
Tata India Pharma & Healthcare Fund Direct Growth | 2.49 | 3.78 | 4.92 |
As on April 2025
The alpha for Tata India Pharma & Healthcare Fund Direct Growth is calculated against Nifty Pharma TR INR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
Tata India Pharma & Healthcare Fund Direct Growth | 1 | 0.95 | 0.91 |
As on April 2025
The Beta for Tata India Pharma & Healthcare Fund Direct Growth is calculated with Nifty Pharma TR INR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
Tata India Pharma & Healthcare Fund Direct Growth | 0.59 | 0.91 | 1.09 |
As on April 2025
The sharpe ratio for Tata India Pharma & Healthcare Fund Direct Growth is calculated with Nifty Pharma TR INR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Tata India Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
Tata India Pharma & Healthcare Fund Direct Growth | 20.6 | 16.72 | 16.11 |
As on April 2025
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.59 as on April 2025. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 1.26 as on April 2025. It tells the consistency of the fund in generating superior risk-adjusted performance
Meeta Shetty is the fund manager of Tata India Pharma & Healthcare Fund Direct Growth
The Exit load of Tata India Pharma & Healthcare Fund Direct Growth is 0.25%